Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025

Reuters

05-31

Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025

Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539978618"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539978618\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539978618?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-31 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539978618","market":"us","top_or_hot":-1,"title":"Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-31 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDLvRf40:1","article_id":"2539978618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539978618","pubTimestamp":1748692864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields  therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology  Annual Meeting and published in the Journal of Clinical Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4548":"巴美列捷福持仓","NVCR":"NovoCure Limited","BK4082":"医疗保健设备","BK4534":"瑞士信贷持仓"},"translate_title":"Novocure Ltd.计划到2025年在美国向监管机构提交TTFields治疗胰腺癌的申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Novocure Ltd. Plans Regulatory Filing for TTFields Therapy in Pancreatic Cancer in U.S. by 2025\n    \n\n        Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250531920957) on May 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}